Accolade Past Earnings Performance

Past criteria checks 0/6

Accolade's earnings have been declining at an average annual rate of -39.2%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 29.8% per year.

Key information

-39.2%

Earnings growth rate

29.7%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate29.8%
Return on equity-28.2%
Net Margin-31.6%
Next Earnings Update25 Apr 2024

Recent past performance updates

Recent updates

Accolade: Staying Bullish On Favorable Developments

Apr 05

Why We're Not Concerned About Accolade, Inc.'s (NASDAQ:ACCD) Share Price

Feb 17
Why We're Not Concerned About Accolade, Inc.'s (NASDAQ:ACCD) Share Price

Accolade: Remain Confident That FY25 Guided Growth Is Achievable

Jan 17

Accolade: Turning Bullish After Beat-And-Raise Quarter (Rating Upgrade)

Jan 11

Why Investors Shouldn't Be Surprised By Accolade, Inc.'s (NASDAQ:ACCD) 27% Share Price Surge

Jun 13
Why Investors Shouldn't Be Surprised By Accolade, Inc.'s (NASDAQ:ACCD) 27% Share Price Surge

Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?

May 02
Is There Now An Opportunity In Accolade, Inc. (NASDAQ:ACCD)?

An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued

Feb 05
An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 28% Undervalued

Accolade: Inching Closer To Profitability

Oct 17

Accolade Q2 2023 Earnings Preview

Oct 05

Accolade: Fair And Reasonably Priced, But Needs More Time

Aug 09

Accolade Q1 2023 Earnings Preview

Jun 29

Accolade: Little Recent Applause

Mar 28

Accolade Impresses With Revenue Growth But Faces Operating Losses

Dec 16

Accolade: I May Add To My Position

Oct 18

Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets

Jul 11
Accolade, Inc. (NASDAQ:ACCD) Just Reported And Analysts Have Been Lifting Their Price Targets

Accolade, Inc. 2021 Q4 - Results - Earnings Call Presentation

May 06

Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation

Mar 19
Here's Why We're Not Too Worried About Accolade's (NASDAQ:ACCD) Cash Burn Situation

Is Accolade, Inc. (NASDAQ:ACCD) Popular Amongst Institutions?

Jan 15
Is Accolade, Inc. (NASDAQ:ACCD) Popular Amongst Institutions?

Accolade is up 7% on acquisition of 2nd.MD

Jan 14

Accolade Inc.: Bullish Outlook As Its HealthTech Platform Helps Companies Save

Jan 12

Accolade, Inc. 2021 Q3 - Results - Earnings Call Presentation

Jan 11

Accolade Q3 2021 Earnings Preview

Jan 06

Revenue & Expenses Breakdown
Beta

How Accolade makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ACCD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Nov 23388-12316398
31 Aug 23380-14216699
31 May 23371-15517098
28 Feb 23363-46017599
30 Nov 22358-46418898
31 Aug 22350-40118997
31 May 22336-41719095
28 Feb 22310-12317384
30 Nov 21275-9313875
31 Aug 21230-13211065
31 May 21194-857855
28 Feb 21170-516350
30 Nov 20156-485745
31 Aug 20147-505743
31 May 20140-495642
29 Feb 20133-515642
30 Nov 19123-565543
28 Feb 1995-564336
28 Feb 1877-614331

Quality Earnings: ACCD is currently unprofitable.

Growing Profit Margin: ACCD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ACCD is unprofitable, and losses have increased over the past 5 years at a rate of 39.2% per year.

Accelerating Growth: Unable to compare ACCD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACCD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.1%).


Return on Equity

High ROE: ACCD has a negative Return on Equity (-28.23%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.